Infliximab in the treatment of amyloidosis secondary to Crohn's disease;Utilidad del infliximab en el tratamiento de la amiloidosis secundaria en la enfermedad de Crohn

Nefrologia

Volumn 32, Issue 3, 2012, Pages 385-388

  Cabezuelo, Juan B ^a   Egea, Juan P ^b   Ramos, Fernanda ^a   Torrella, Emilio ^b   Muray, Salomé ^a   Alcázar, Concepción ^a  

^a HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b HOSPITAL MORALES MESEGUER   (Spain)

Author keywords

Crohn's disease; Infliximab; Secondary amyloidosis

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MONOCLONAL ANTIBODY; SERUM AMYLOID A;

ADULT; AMYLOIDOSIS; ARTICLE; CASE REPORT; CHRONIC KIDNEY FAILURE; CROHN DISEASE; DRUG COMBINATION; DRUG EFFECT; DYSPHAGIA; HUMAN; MALE; PATHOLOGY; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADULT; AMYLOIDOSIS; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CROHN DISEASE; DEGLUTITION DISORDERS; DRUG THERAPY, COMBINATION; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM; SERUM AMYLOID A PROTEIN;

EID: 84864526487     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2012.Feb.11332     Document Type: Article

References (13)

1. Greenstein AJ, Sachar DB, Panday AKN, Dikman SH, Meyers S, Heimann T, et al. Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine (Baltimore) 1992;71:261-70.
2. Wester AL, Vatn MH, Fausa O. Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998. Inflamm Bowel Dis 2001;7:295-300.
3. Serra I, Oller B, Mañosa M, Naves JE, Zabana Y, Cabré E, et al. Systemic amyloidosis in inflammatory bowel disease: Retrospective study on its prevalence, clinical presentation, and outcome. J Crohns Colitis 2010;4:269-74.
4. Fernández-Nebro A, Tomero E, Ortiz-Santamaría V, Castro MC, Olivé A, de Haro M, et al. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med 2005;118:552-6.
5. Boscá MM, Pérez-Baylach CM, Solís MA, Antón R, Mayordomo E, Pons S, et al. Secondary amyloidosis in Crohn's disease: treatment with tumour necrosis factor inhibitor. Gut 2006;55:294-5.
6. Iizuka M, Konno S, Horie Y, Itou H, Shindo K, Watanabe S. Infliximab as a treatment for systemic amyloidosis associated with Crohn's disease. Gut 2006;55:744-5.
7. Park YK, Han DS, Eun CS. Systemic amyloidosis with Crohn's disease treated with infliximab. Gut 2008;14:431-2.
8. Iizuka M, Sagara S, Etou T. Efficacy of Scheduled infliximab maintenance therapy on systemic amyloidosis associated with Crohn's disease. Inflamm Bowel Dis 2011;17:E67-E68.
9. Basturk T, Ozagari A, Ozturk T, Kusaslan R, Unsal A. Crohn's disease and secondary amiloidosis: early complication? A case report an review of the literature. J Ren Care 2009;35:147-50.
10. Dember LM, Hawkins PH, Hazenberg BPC, Gorevic PD, Merlini G, Butrimiene I, et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007;356:2349-60.
11. Fidalgo C, Calado J, Cravo M. Secondary amyloidosis in a patient with long duration Crohn's disease treated with infliximab. Biodrugs 2010;24 Suppl 1:15-7.
12. Sandborn W, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146(12):829-38.
13. Lachmann HJ, Goodman HJB, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361-71.